Eli Lilly raised its financial outlook for the third time this year as Zepbound sales surged. The drug continues to lead the U.S. prescription weight-loss market.
4:22 PMMarketWatch22 stories from 8 sources
Drug demand surged as regulators tightened healthcare’s rules
Day’s Recap
The day’s central tension was clear: pharmaceutical growth is accelerating while regulators and purchasers gain more influence over how care is approved, paid for, and monitored.
Supporting Articles
Abdul El-Sayed, a Democratic Senate candidate in Michigan, is challenging Robert F. Kennedy Jr.'s claims and criticizing the FDA's new enforcement policy on peptides. The dispute combines a campaign contest with a fight over how regulators should treat the products.
10:18 AMStat News
The Department of Health and Human Services has authorized six peptides despite objections from FDA career scientists. The decision gives the rapidly growing peptide market a regulatory boost while exposing disagreement within the federal health bureaucracy over safety and oversight.
9:43 AMStat News
A federal judge rejected regulators' revised definition of frailty used to determine which people with medical conditions could be exempt from Medicaid work requirements. The ruling found that federal regulators exceeded their authority by narrowing those exceptions.
2:57 PMStat News
Medicare is testing AI-assisted prior authorization to identify potentially wasteful medical spending. The trial was associated with a large decline in the use of medical services.
1:10 PMMarketWatch
A new federal rule will require pharmacy benefit managers to disclose fees, compensation, and other payment details that have generally remained private. The policy is aimed at exposing financial flows in the prescription-drug supply chain.
12:44 PMStat News
Vertex's kidney disease drug is facing close review over a potential infection risk ahead of the FDA's November 30 approval decision. Regulators must weigh the drug's potential benefits against the seriousness and manageability of that safety concern.
9:25 AMStat News4:22 PMMarketWatch
Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock closed at a record high.
Summary
Eli Lilly raised its financial outlook for the third time this year as Zepbound sales surged. The drug continues to lead the U.S. prescription weight-loss market.
Repeated outlook increases signal that demand is exceeding Lilly's earlier assumptions, not merely meeting them.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Zepbound's lead is translating rapid adoption of weight-loss medicines into a major and still-expanding revenue stream.
4 stories · 3 sources
10:18 AMStat News
STAT+: El-Sayed claps back at RFK Jr., and FDA’s ‘enforcement discretion’ on peptides
Summary
Abdul El-Sayed, a Democratic Senate candidate in Michigan, is challenging Robert F. Kennedy Jr.'s claims and criticizing the FDA's new enforcement policy on peptides. The dispute combines a campaign contest with a fight over how regulators should treat the products.
El-Sayed's response turns peptide enforcement into a test of Kennedy's public health credibility and the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The fight links a niche drug policy to a broader Senate debate over evidence, regulation, and Kennedy's influence over health policy.
9:43 AMStat News
STAT+: HHS green lights six peptides, despite concerns from FDA scientists
Summary
The Department of Health and Human Services has authorized six peptides despite objections from FDA career scientists. The decision gives the rapidly growing peptide market a regulatory boost while exposing disagreement within the federal health bureaucracy over safety and oversight.
HHS has prioritized access to six peptides even as FDA scientists raise safety concerns, signaling
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The move may set a precedent for political leadership to expand access despite dissent from career regulators.
2:57 PMStat News
STAT+: Federal judge rejects new Medicaid ‘frailty’ definition for work requirements
Summary
A federal judge rejected regulators' revised definition of frailty used to determine which people with medical conditions could be exempt from Medicaid work requirements. The ruling found that federal regulators exceeded their authority by narrowing those exceptions.
The decision blocks a regulatory approach that would have exposed more medically vulnerable Medicaid recipients
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The ruling could preserve Medicaid coverage for people whose medical limitations do not fit a narrow administrative definition of disability.
1:10 PMMarketWatch
Medicare used AI to pre-approve patient care, and it immediately led to a large drop in medical services
Summary
Medicare is testing AI-assisted prior authorization to identify potentially wasteful medical spending. The trial was associated with a large decline in the use of medical services.
The sharp reduction suggests AI can materially change utilization when it helps determine which care
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
AI could lower Medicare spending quickly, but its value depends on cutting inappropriate care without creating new barriers for patients.
12:44 PMStat News
STAT+: New federal rule will require prescription drug middlemen to share secret payments data
Summary
A new federal rule will require pharmacy benefit managers to disclose fees, compensation, and other payment details that have generally remained private. The policy is aimed at exposing financial flows in the prescription-drug supply chain.
The rule moves PBM compensation from a largely private contractual matter into a regulated disclosure
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Revealing hidden PBM payments could reshape negotiations across the drug supply chain and increase pressure for lower prices.
9:25 AMStat News
STAT+: Vertex kidney disease drug scrutinized for infection risk
Summary
Vertex's kidney disease drug is facing close review over a potential infection risk ahead of the FDA's November 30 approval decision. Regulators must weigh the drug's potential benefits against the seriousness and manageability of that safety concern.
The infection signal has become a central factor in the drug's approval case, not a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The decision will shape access to a potentially important kidney treatment and establish how regulators handle its infection risk.
Other Developments
A curated list of other prominent stories from this day.
Cognitive reserve describes the brain's ability to maintain function despite age-related neuronal decline. Education, mentally demanding activities, social engagement, and other experiences may help preserve that adaptability.
1:29 PMChief Executive
AI agents are beginning to handle parts of elder care as families confront high costs, limited access, and uneven caregiving burdens. Early results suggest these tools could support some responsibilities now carried by relatives and professional caregivers.
10:00 AMPYMNTS
Scientists identified a weakened brain signal associated with sensory processing problems, disorganized speech, and greater symptom severity in schizophrenia. The finding offers a possible biological link among symptoms that are usually treated as separate.
9:14 AMScienceDaily
A study of nearly 13,000 adults found that those consuming the most artificial sweeteners experienced a 62% faster decline in memory and thinking skills, equivalent to about 1.6 additional years of brain aging. The study identified links involving six sweeteners but did not establish that the products caused cognitive decline.
9:04 AMScienceDaily
In a study of more than 87,000 adults, greater exposure to bright daylight was associated with a 16% lower risk of dementia. Less than 42 minutes of bright daylight was associated with higher risk and reportedly outperformed six established risk factors as a predictor, though the study does not prove that light exposure prevents dementia.
7:30 AMScienceDaily
Merck exceeded quarterly estimates and raised its profit outlook as Keytruda generated stronger-than-expected sales. The newer injectable version also showed early strength.
7:24 AMCNBC
Researchers found that pure, unsweetened cranberry juice slowed the regrowth of plaque bacteria and reduced their production of enamel-damaging acids in laboratory testing. Proanthocyanidins, natural cranberry compounds, may disrupt the bacteria involved in tooth decay.
7:12 AMScienceDaily
Researchers created a detailed atlas of colorectal tumors to examine why cancers in younger patients can be more aggressive. The work offers new insight into the biological differences behind those outcomes.
6:00 AMStat News
Biopharma companies disagree over how Treasury’s proposed China restrictions would affect the industry, with an exemption for a common deal structure at the center of the dispute.
4:30 AMStat News
The opinion argues that health care purchasers must reject excessive prices and unfavorable terms if they want to force change. It says the industry’s largest players have little incentive to reform themselves.
4:30 AMStat News
Rising health care costs are pushing affordability to the center of voter concerns after years of limited political action. Voters are increasingly open to more sweeping solutions to the crisis.
4:30 AMStat News
Malaysian hospital operator Asia OneHealthcare filed a draft prospectus for an IPO of up to 4.38 billion shares on Bursa Malaysia. The TPG-backed company plans to use proceeds from the new shares for hospital expansion, facility upgrades, debt repayment and offering costs, and operates 23 hospitals.
1:33 AMEconomic Times1:29 PMChief Executive
Cognitive Reserve: What It Is And How To Build It
Summary
Cognitive reserve describes the brain's ability to maintain function despite age-related neuronal decline. Education, mentally demanding activities, social engagement, and other experiences may help preserve that adaptability.
The practical shift is from treating cognitive aging as a fixed biological decline to focusing
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Cognitive reserve reframes brain aging as partly shaped by lifelong habits rather than biology alone.
10:00 AMPYMNTS
AI Is Stepping Up to Care for the Elderly
Summary
AI agents are beginning to handle parts of elder care as families confront high costs, limited access, and uneven caregiving burdens. Early results suggest these tools could support some responsibilities now carried by relatives and professional caregivers.
The opportunity lies in using AI to extend limited caregiving capacity, not replace human care
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
AI could ease a growing care shortage, but failures in elder care carry unusually high human costs.
9:14 AMScienceDaily
A single brain signal may explain schizophrenia's most puzzling symptoms
Summary
Scientists identified a weakened brain signal associated with sensory processing problems, disorganized speech, and greater symptom severity in schizophrenia. The finding offers a possible biological link among symptoms that are usually treated as separate.
A shared neural signal could give researchers a more precise way to classify schizophrenia and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A reliable cross-symptom marker could improve diagnosis and treatment selection in a disorder with highly variable presentations.
9:04 AMScienceDaily
Six popular sugar substitutes linked to faster brain aging
Summary
A study of nearly 13,000 adults found that those consuming the most artificial sweeteners experienced a 62% faster decline in memory and thinking skills, equivalent to about 1.6 additional years of brain aging. The study identified links involving six sweeteners but did not establish that the products caused cognitive decline.
The finding adds a potential long-term health concern to the debate over replacing sugar with
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The study could influence dietary guidance, but it is not strong enough on its own to prove that artificial sweeteners accelerate brain aging.
7:30 AMScienceDaily
Less than 42 minutes of bright daylight linked to higher dementia risk
Summary
In a study of more than 87,000 adults, greater exposure to bright daylight was associated with a 16% lower risk of dementia. Less than 42 minutes of bright daylight was associated with higher risk and reportedly outperformed six established risk factors as a predictor, though the study does not prove that light exposure prevents dementia.
The result suggests that daylight exposure could serve as a low-cost, modifiable marker of dementia
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
If confirmed, daylight could become an accessible target for dementia prevention, but the current evidence remains associative.
7:24 AMCNBC
Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Summary
Merck exceeded quarterly estimates and raised its profit outlook as Keytruda generated stronger-than-expected sales. The newer injectable version also showed early strength.
The injectable formulation gives Merck another way to sustain Keytruda's commercial momentum and potentially improve
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A successful new formulation can protect a major cancer drug franchise while changing treatment logistics for patients and providers.
7:12 AMScienceDaily
Scientists discover that cranberry juice may help fight tooth decay
Summary
Researchers found that pure, unsweetened cranberry juice slowed the regrowth of plaque bacteria and reduced their production of enamel-damaging acids in laboratory testing. Proanthocyanidins, natural cranberry compounds, may disrupt the bacteria involved in tooth decay.
The evidence points to a possible preventive role for cranberry compounds, but laboratory effects do
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The finding may support new cavity-prevention products, but it does not justify treating sweetened cranberry drinks as dental care.
6:00 AMStat News
STAT+: New atlas of colorectal tumors sheds light on why cancers in young people are more dangerous
Summary
Researchers created a detailed atlas of colorectal tumors to examine why cancers in younger patients can be more aggressive. The work offers new insight into the biological differences behind those outcomes.
The atlas shifts the question from rising case counts to the tumor features that may
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Understanding why colorectal cancer behaves more aggressively in younger people could improve diagnosis and treatment as cases rise in that population.
4:30 AMStat News
STAT+: Biopharma industry at odds over impact of Treasury’s new China rule
Summary
Biopharma companies disagree over how Treasury’s proposed China restrictions would affect the industry, with an exemption for a common deal structure at the center of the dispute.
The exemption could determine whether companies can continue using a widely used partnership or investment
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The rule’s treatment of one deal structure could reshape how biopharma companies manage their China exposure.
4:30 AMStat News
Opinion: Health care needs buyers willing to say no
Summary
The opinion argues that health care purchasers must reject excessive prices and unfavorable terms if they want to force change. It says the industry’s largest players have little incentive to reform themselves.
The argument shifts responsibility toward employers, insurers, and other buyers that control large portions of
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Concentrated purchasing power may be one of the few practical levers for challenging entrenched health care prices.
4:30 AMStat News
Politicians have failed to tackle health care affordability. It’s now voters’ rallying cry
Summary
Rising health care costs are pushing affordability to the center of voter concerns after years of limited political action. Voters are increasingly open to more sweeping solutions to the crisis.
The political shift reflects a widening gap between household costs and incremental policy responses. Candidates
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Affordability is becoming a political demand for structural change rather than another promise of modest cost relief.
1:33 AMEconomic Times
Global Market: Malaysia's Asia OneHealthcare files draft prospectus for IPO of up to 4.38 billion shares
Summary
Malaysian hospital operator Asia OneHealthcare filed a draft prospectus for an IPO of up to 4.38 billion shares on Bursa Malaysia. The TPG-backed company plans to use proceeds from the new shares for hospital expansion, facility upgrades, debt repayment and offering costs, and operates 23 hospitals.
The filing gives Asia OneHealthcare access to public-market capital as it returns to profitability and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Asia OneHealthcare is positioning public capital as the next source of growth for Malaysia's hospital sector.
Make it yours
Build Your First Pass.
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!